SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is trending following major developments like its debut on Ethereum's new EIL testnet and the launch of ReacDEFI for automated stop orders on DEXes, showcasing its innovative 'Reactive Smart Contracts' for on-chain automation. The community actively highlights $REACT's 'hidden gem' status, limited supply, and increasing holder count, anticipating significant growth as arbitrage trading ends and its role in unifying Ethereum's infrastructure becomes more recognized.

AXS is the governance token for the Axie Infinity game. Token holders will be able to shape and vote for the direction of the game universe. This is unlike traditional games where all decisions are made by the game developers. AXS holders will be able to stake their tokens to earn more AXS and even vote for governance proposals.

Axie Infinity

Axie Infinity (AXS) is trending as the community anticipates significant upside potential driven by recent developments, including its integration with Apple Vision Pro, the launch of its V4 engine, and ongoing ecosystem enhancements on the Ronin network. Discussions highlight these strategic advancements and the platform's evolving role within the broader Web3 gaming and AI sectors.

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Sutro Biopharma is trending following its recent reverse stock split and successful regaining of Nasdaq compliance, coupled with a strategic shift to prioritize its next-generation ADC pipeline. The community is actively discussing the implications of these moves, with some viewing the low float as a catalyst for potential upside, while others express caution regarding the company's past performance and restructuring. Investors are keenly awaiting updates on potential partnerships for its deprioritized Luvelta asset and anticipating significant milestones from existing collaborations.

Based Chad

CHAD is experiencing a surge in community conversation, largely fueled by its strong affiliation with Coinbase, including executives actively holding and promoting the token, and Coinbase itself featuring CHAD memes. The community is buzzing about CHAD's unique buyback mechanisms, upcoming video game releases, and its notable resilience during broader market downturns, with many proclaiming "billions is programmed" for this universally recognized meme. Amid discussions of an impending supply shock and potential Base airdrop incentives, CHAD is seen by many as a leading contender for substantial growth within the memecoin ecosystem.

Leonardo DRS, Inc. engages in the provision of defense products and technologies. It develops and manufactures defense products for the U.S. military, intelligence agencies and allies around the world. Its broad technology portfolio focuses on advanced sensing, network computing, force protection, and electrical power and propulsion, as well as a range of key defense priorities. The company operates through the Advanced Sensors and Computing and Integrated Mission Systems segments. The Advanced Sensors and Computing segment have been aligned to push towards a more autonomous future. It consists of six business units, which include Airborne & Intelligence Systems, Daylight Solutions, DRS RADA Technologies, Electro-Optical & Infrared Systems, Land Electronics, and Naval Electronics. The Integrated Mission Systems segment consists of both a ground vehicle integrator and naval power and propulsion system provider. The company was founded by Leonard Newman and David E. Gross in 1969 and is headquartered in Arlington, VA.

Leonardo DRS Inc.

Leonardo DRS is currently trending due to its strong positioning within the accelerating global defense sector, highlighted by recent multi-billion dollar contract awards for critical naval propulsion systems and advanced weapon sights. The investment community views the company as an undervalued player with a robust backlog, anticipating significant growth fueled by increasing defense budgets and its diverse technological offerings. Discussions center on its potential for improved execution under new leadership and its role in key areas like counter-UAS and radar technology.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending lower following recent analyst downgrades and intensified concerns over AI competition, notably with Apple launching a new creative software bundle. While some investors fear AI will decimate Adobe's subscription-based business, many others view the sharp decline as an oversold condition, highlighting the company's robust fundamentals and ongoing AI innovation as a rare buying opportunity amidst the broader software sector weakness.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic (LUNC) is experiencing significant market interest, fueled by ongoing legal developments concerning its co-founder and continued token burn initiatives by major exchanges like Binance. The community is vigorously pushing for a "redemption story," emphasizing ecosystem advancements such as the upcoming LUNCVERSE launch and the passed Terra Classic Forex proposal, alongside intense discussions about supply reduction and its path to long-term revival.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant is trending as community discussion highlights its pivotal role in the UK's Tokenized Deposit Pilot (GBTD) and its Overledger technology, which is facilitating interoperability for major financial institutions like HSBC and Barclays. Many proponents are emphasizing Quant's foundational infrastructure for real-world assets and digital currencies, alongside its limited token supply, as key drivers for substantial future value. Despite some impatience over current price consolidation, the ongoing enterprise adoption is seen by many as a long-term accumulation opportunity, anticipating significant growth as global institutional integration advances.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is a hot topic following a pivotal long-term data center lease agreement with AMD, marking its strategic transition into high-performance computing and AI infrastructure. The community is actively discussing how this deal, partly funded by Bitcoin sales, validates Riot's massive power capacity and positions it as a key player in meeting the surging demand for AI data centers. This move reinforces the company's shift beyond traditional crypto mining, with many anticipating further expansion and new tenant agreements.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding Company (SCLX) is actively trending amid ongoing strategic adjustments, including the recent full repayment of a significant obligation, securing an expanded loan facility backed by its Datavault AI (DVLT) stake, and withdrawing a securities offering. The community is sharply divided, with bulls interpreting these moves as a strategic cleanup and prelude to a major short squeeze, while bears view them as desperate measures by management to address persistent financial hurdles. Key discussions also revolve around the potential implications of the upcoming Dream Bowl meme coin distribution for shareholders and the recent appointment of high-profile legal counsel for both SCLX and DVLT.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small Cap Stocks To Keep An Eye On - December 4th

SMX (Security Matters) Public, Spring Valley Acquisition, Direxion Daily META Bull 2X Shares, Polyrizon, and Direxion Daily TSLA Bear 1X Shares are the five Small Cap stocks to watch today, according...

Top Biotech Stocks To Consider - December 4th

Danaher, Polyrizon, Vertex Pharmaceuticals, Medpace, Abivax, Capricor Therapeutics, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Polyrizon Stock Skyrockets After New Data Shows Naloxone Gel Outperforms Marketed Spray

Polyrizon stock is up on new data showing its naloxone hydrogel formulation has stronger and longer-lasting mucosal retention.read more...

What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?

Polyrizon surged in nearly 140% after-hours trading following preclinical data showing its naloxone hydrogel outperforms a marketed spray and a key manufacturing milestone.read more...

Polyrizon Hits Key Breakthrough That Brings Its Nasal Spray Closer To 2026 Trials

Polyrizon jumps over 100%. The company completes major manufacturing milestone for its proprietary nasal-spray product platform.read more...

<ul class="summary-bullets"><li>The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes.</li><li>Following the update, Polyrizon’s stock traded over 82% higher in Tuesday’s premarket.</li><li>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026.</li></ul>Polyrizon (PLRZ) announced on Tuesday a major manufacturing milestone for its proprietary nasal spray platform, bringing the company closer to supporting upcoming clinical trials and potential commercial availability.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/PLRZ">Polyrizon’s stock</a> traded over 73% higher in Tuesday’s premarket. On Stocktwits, retail sentiment for the stock improved to ‘extremely bullish’ from ‘bullish’ territory, amid ‘high’ message volumes.&nbsp;<h2 class="st-heading-2">Milestone Achievement</h2>Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation.&nbsp;The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes while maintaining the quality standards necessary for clinical trials.<blockquote>"The process validated our manufacturing strategy.”&nbsp;-Tomer Izraeli, CEO, Polyrizon&nbsp;</blockquote>“With this batch in hand, we are energized and prepared to advance into next batches towards clinical trial material manufacturing, which we believe brings us one step closer to addressing the unmet needs in the nasal spray market."<h2 class="st-heading-2">Preparing For Clinical Trials</h2>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026. Polyrizon’s manufacturing procedures align with theU.S. and European regulatory requirements.The PL-14 nasal spray is engineered to create a fast-acting, moisturizing barrier in the nasal cavity, helping trap, isolate, and neutralize airborne allergens before they contact mucosal tissues. Developed using Polyrizon’s proprietary Capture &amp; Contain (C&amp;C) bio-adhesive technology, the spray offers extended, non-pharmacological protection for people exposed to high levels of environmental allergens.&nbsp;PLRZ stock has lost over 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mongodb-stock-rises-premarket-as-analysts-increase-price-targets/cLIajIsRE0t">MongoDB’s Atlas Engine Drives A Wave Of Price Target Hikes – Stock Pops In Premarket Trade</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Polyrizon Stock Soar Pre-Market Today? 

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 

Equity

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 


Polyrizon Ltd (PLRZ)&nbsp;led the pack with a 23% increase in weekly followers after the development-stage biotech company dropped plans to undergo a 1-for-10 reverse stock split, which led to shares surging nearly fourfold on Friday.The Israel-based company specializes in preventing biological threats, including allergens and viruses, from penetrating mucosal tissues — an area that has gained new relevance in the post-COVID-19 world.Last month, Polyrizon reported promising preliminary safety results for its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/plrz-stock-surges-on-manufacturing-deal-for-trial/cJaVyHWR1U">PL-14</a> Allergy Blocker, a mucoadhesive nasal gel spray designed to create a physical barrier against airborne allergens. The company expects to launch clinical trials in the U.S. and Europe by late 2025 or early 2026.Polyrizon stock has lost over half its value this year.Pheton Holdings (PTHL)&nbsp;saw a 19% rise in retail follower growth over the past week despite the absence of any news catalyst.The Beijing, China-based healthcare solution provider specializes in treatment planning systems for brachytherapy and other related products and services.The company's shares debuted on the Nasdaq in September 2024 and have gained a little over 4% since. However, their performance has been less than stellar year to date, with a loss of over 5%.AirSculpt Technologies (AIRS)&nbsp;posted an 8% jump in weekly Stocktwits follower additions. The body contouring specialist reported better-than-expected quarterly results and forecast full-year revenue of about $160 million to $170 million, which topped Wall Street estimates.Shares of the Miami Beach, Florida-based company, which offers minimally invasive fat removal procedures, have lost over 42% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest

A trio of small-cap healthcare stocks caught the attention of retail investors last week, posting sharp jumps in follower growth on Stocktwits. 

Shares of Polyrizon skyrocketed more than 200% to an all-time high on Wednesday, making it the top biotech stock with the most new followers on Stocktwits in the past 24 hours.&nbsp;Trading volume surged 890 times the daily average, reflecting heightened investor interest in the Israel-based biotech company.The massive rally follows Polyrizon’s announcement of a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a prominent European Good Manufacturing Practice (GMP) manufacturer.&nbsp;This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.The PL-14 allergy blocker is part of Polyrizon’s effort to develop innovative nasal sprays that create a hydrogel-based shield in the nasal cavity, protecting against allergens and viruses.&nbsp;The manufacturing deal secures a compliant supply chain for the clinical trial, marking a key milestone for the development-stage biotech firm.Retail chatter on Stocktwits has been overwhelmingly bullish.<stembedurl>https://stocktwits.com/TraderUKBoyy/message/597012617</stembedurl><stembedurl>https://stocktwits.com/Dollarpee/message/597017164</stembedurl>Polyrizon’s stock had a rocky start on the Nasdaq, debuting at the end of October with a disappointing IPO.&nbsp;The company priced 958,903 units at $4.38 per unit, with each unit including one ordinary share and three warrants exercisable at the same price. Shares dropped more than 64% post IPO.Despite the poor debut, Polyrizon has gained 90% so far this year following Wednesday’s surge, although it remains below its IPO price.&nbsp;Over the past month, the stock has seen a meteoric rise in popularity, adding 1,576% more followers on Stocktwits amid a 10,300% spike in message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial

This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Current Price	$15.55
Prev Close	$15.54
Open	$15.00
Dividend Yield	0.00%
50-Day Moving Average	$8.75
Beta	-1.26
Avg. Volume	8.72M
PE Ratio	-0.05

52-Week High	$2,550.00
52-Week Low	$2.88
Market Capitalization	$24.79M
EPS (Annual)	-$552.51
Price to Book	0.83
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PLRZ
Polyrizon Ltd. Ordinary Shares

Feed

News

Sentiment

Fundamentals

Info

Latest PLRZ News

PLRZPolyrizon Ltd. Ordinary Shares